Table 2 Median time to continued improvement events (Kaplan–Meier analysis)
Improvement threshold | Median time, weeks (interquartile range) | p value | |
|---|---|---|---|
Tofacitinib 5 mg BID (N = 133) | Placebo-to-tofacitiniba (N = 136) | ||
≥ 30% improvement | |||
Total back painb | 8 (2–32) | 24 (16–NE) | < 0.0001 |
Nocturnal painb | 4 (2–40) | 24 (16–NE) | < 0.0001 |
≥ 50% improvement | |||
Total back painb | 24 (4–NE) | NE | 0.0003 |
Nocturnal painb | 12 (4–NE) | 40 (24–NE) | < 0.0001 |
BASDAI questions | |||
Fatigue (Q1) | 40 (8–NE) | NE | 0.0212 |
Spinal pain (Q2) | 24 (4–NE) | NE | < 0.0001 |
Peripheral joint pain/swelling (Q3) | 16 (4–NE) | 32 (12–NE) | 0.0711 |
Enthesitis (Q4) | 14 (4–NE) | 40 (16–NE) | 0.0017 |
Morning stiffness (Q5 and Q6)c | 24 (4–NE) | NE | 0.0037 |
BASDAI total score | 24 (8–NE) | NE | 0.0016 |
Improvement in ASDAS | |||
≥ 1.1 points | 8 (2–NE) | 24 (24–NE) | < 0.0001 |
≥ 2.0 points | NE | NE | 0.2494 |